- Faculty
- Health
- In the News
Phase Ib Study of XMT-1660 in Solid Tumors Likely to Express B7-H4
Ritesh Parajuli
A Study On:
- Lip, Oral Cavity and Pharynx
- Colon
- Pancreas
- Larynx
- Soft Tissue
- Corpus Uteri
- Stomach
- Lung
- Rectum
- Anus
- Other Digestive Organ
- Ovary
- Brain and Nervous System
- Other Respiratory and Intrathoracic Organs
- Other Urinary
- Bones and Joints
- Other Male Genital
- Thyroid
- Unknown Sites
- Ill-Defined Sites
- Melanoma, Skin
- Liver
- Other Skin
- Kidney
- Breast
- Esophagus
- Small Intestine
- Cervix
- Other Female Genital
- Prostate
- Urinary Bladder
- Eye and Orbit
- Other Endocrine System
Status:
- Open
Eligibility
Adults
Interested in joining this trial?
Official Title
A Phase Ib, First-In-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors
Details
A Study of XMT-1660 in Solid Tumors
Eligibility
You can join if...
Inclusion Criteria-Participants must be at least 18 years of age
-Participant has proven recurrent or advanced solid tumor and has disease progression
after treatment with available anti-cancer therapies known to confer benefit or is
intolerant to treatment
-Participant must be willing to undergo a minimally invasive tumor biopsy to obtain tumor
tissue for local testing, if medically feasible, prior to C1D1.
Exclusion Criteria
-Participant has received prior treatment with another ADC containing an auristatin or
maytansinoid payload (e.g., mirvetuxuximab)
-Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy within 14 days of starting study treatment.
-Participants with human immunodeficiency virus (HIV) infection are excluded from
study entry. An HIV test is required during Screening
Get in touch with our study team
News & Events
UCI Health enrolls patient in first U.S. study of medical device for erectile dysfunction Sickle cell disease treatment nearing FDA approval - Faculty
- Health
- In the News
His GERD is now a distant memory - Faculty
- Health
- In the News